Accessibility Menu
Cspc Pharmaceutical Group logo

Cspc Pharmaceutical Group(OTC) CSPCY

Current Price$4.31
Market Cap$12.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+72%
5 Year-7%
1 Year+4%
1 Month+26%
Cspc Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeUSD 4.312026-07-24
Cspc Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.38%USD 4.092026-07-17
1 month+26.11%USD 3.422026-06-24
3 month-2.94%USD 4.442026-04-24
Year to date+2.24%USD 4.222025-12-31
1 year+4.08%USD 4.142025-07-24
3 year+49.97%USD 2.872023-07-25
5 year-7.19%USD 4.642021-07-23
Since inception+72.3%USD 2.502018-12-28

Cspc Pharmaceutical Group Financials at a Glance

Market Cap

$12.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥44.14B

Net Income (TTM)

CN¥5.98B

EPS (TTM)

$0.19

P/E Ratio

22.89

Dividend

$0.15

Beta (Volatility)

0.47 (Low)

Price

$4.31

Volume

463

Open

$4.31

Previous Close

$4.31

Daily Range

$4.31 - $4.31

52-Week Range

$3.26 - $5.83

Estimated Earnings Date

Aug 14, 2024

CSPCY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cspc Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a leading investment holding company engaged in the manufacture and sale of pharmaceutical products across various regions, including Mainland China, Europe, and North America. The company operates through multiple segments, providing a diverse range of medications and healthcare services.

Products and Services
  • Manufactures finished drugs and bulk products for various medical conditions
  • Offers functional food products and healthcare services
  • Collaborates with AstraZeneca for novel drug development
Growth Outlook
  • Revenue of CNY 12.49 billion in Q4 2025, showing strong market demand
  • Net income increased to CNY 1.31 billion in Q4 2025, reflecting operational efficiency
  • Strategic partnerships expected to enhance product pipeline and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 45.67 billion, indicating robust growth
  • Net profit margin of 14.92% TTM, showcasing effective cost management
  • Dividend yield of 3.39% TTM, appealing for income-focused investors
CSPC Pharmaceutical Group Limited has established itself as a significant player in the biotechnology industry, with a comprehensive portfolio of pharmaceutical products. The company's strategic collaborations, particularly with AstraZeneca, position it well for future growth and innovation. Recent financial performance highlights a strong revenue trajectory and profitability, making it an attractive option for potential investors interested in the healthcare sector. The company's commitment to research and development further enhances its potential for long-term success.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19,700

CEO

Lei Cai, PhD

Website

www.cspc.com.hk

Headquarters

Shijiazhuang, HE 050035, CN

CSPCY Financials

Key Financial Metrics (TTM)

Gross Margin

65.59%

Operating Margin

15.26%

Net Income Margin

14.92%

Return on Equity

11.47%

Return on Capital

11.41%

Return on Assets

8.16%

Earnings Yield

4.37%

Dividend Yield

3.44%

Payout Ratio

64.44%

Stock Overview

Market Cap

$12.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.88B

Volume

463

Avg. Volume

1.55K

Financials (TTM)

Gross Profit

CN¥37.90B

Operating Income

CN¥9.23B

EBITDA

CN¥12.13B

Operating Cash Flow

CN¥7.87B

Capital Expenditure

-CN¥3.08B

Free Cash Flow

CN¥4.79B

Cash & ST Invst.

CN¥8.87B

Total Debt

CN¥641.32M

Cspc Pharmaceutical Group Performance Analysis

Cspc Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 4,594,329,9966.3%
20232023-12-31CNY 4,438,953,006-3.4%
20242024-12-31CNY 4,030,844,707-9.2%
20252025-12-31CNY 3,617,745,264-10.2%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30109.1%
Q42024-12-31-15.8%
Q22025-06-30-87.8%
Q42025-12-31647.8%
Cspc Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.304.4%
20232023-12-31CNY 0.28-8.0%
20242024-12-31CNY 0.20-26.6%
20252025-12-31CNY 0.19-7.7%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3012.5%
Q42024-12-31-59.3%
Q22025-06-30-74.5%
Q42025-12-31328.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥12.49B

+60.5%

Gross Profit

CN¥8.19B

-56.1%

Gross Margin

65.57%

N/A

Market Cap

$12.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$630.23K

N/A

Employees

19,700

N/A

Net Income

CN¥1.31B

-14.3%

EBITDA

CN¥2.08B

+16.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥8.87B

-32.3%

Total Debt

CN¥641.32M

-9.3%

Accounts Receivable

CN¥9.55B

-5.7%

Inventory

CN¥3.09B

-10.5%

Long Term Debt

CN¥180.75M

+68.8%

Short Term Debt

CN¥460.42M

-23.2%

Return on Assets

8.16%

N/A

Return on Invested Capital

10.67%

N/A

Free Cash Flow

CN¥1.99B

-5.2%

Operating Cash Flow

CN¥2.75B

-4.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ERFSFEurofins Scientific SE
$73.75-0.36%
RCDTFRecordati S.p.A.
$58.00+0.00%
BDUUFBangkok Dusit Medical Services Public Company Limited
$0.64+0.00%
BDULFBangkok Dusit Medical Services Public Company Limited
$0.56+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About CSPCY

What is the current price of Cspc Pharmaceutical Group?

Cspc Pharmaceutical Group is trading at $4.31 per share.

What is the 52-week range for Cspc Pharmaceutical Group?

Over the past 52 weeks, Cspc Pharmaceutical Group has traded between $3.26 and $5.83.

How much debt does Cspc Pharmaceutical Group have?

As of the most recent reporting period, Cspc Pharmaceutical Group reported total debt of CN¥91.74M.

How much cash does Cspc Pharmaceutical Group have on hand?

Cspc Pharmaceutical Group reported CN¥754.52M in cash and cash equivalents in its most recent financial results.

What is Cspc Pharmaceutical Group’s dividend yield?

Cspc Pharmaceutical Group currently has a dividend yield of 3.44%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services